| Recruiting | Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in P NCT06364410 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial NCT06203600 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Recruiting | Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer NCT06329973 | Henan Cancer Hospital | Phase 1 / Phase 2 |
| Recruiting | A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People Wit NCT06251973 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Pati NCT05733000 | Northwestern University | Phase 2 |
| Recruiting | Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Loca NCT05651594 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastati NCT05677490 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Terminated | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors NCT05555251 | BioInvent International AB | Phase 1 / Phase 2 |
| Unknown | Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Ca NCT05342389 | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 2 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Recruiting | Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adeno NCT05041153 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Recruiting | Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction NCT04840264 | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or NCT04535401 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tu NCT04704661 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Adv NCT04660760 | Academic and Community Cancer Research United | Phase 2 |
| Active Not Recruiting | Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca NCT04921904 | Baylor Research Institute | Phase 1 / Phase 2 |
| Recruiting | Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Color NCT04511039 | Roswell Park Cancer Institute | Phase 1 |
| Unknown | Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cance NCT04781686 | Zhou Fuxiang | Phase 2 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Eso NCT04460937 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gast NCT03641313 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers NCT04221893 | University of California, San Francisco | N/A |
| Withdrawn | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma NCT03739801 | University of Southern California | Phase 1 / Phase 2 |
| Active Not Recruiting | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors NCT04007744 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer NCT04220827 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Ga NCT03918499 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pan NCT03337087 | Academic and Community Cancer Research United | Phase 1 / Phase 2 |
| Completed | Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma NCT03395847 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Completed | Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal NCT03008278 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Rec NCT02391038 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Active Not Recruiting | Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal NCT01142388 | National Cancer Institute (NCI) | Phase 2 |